- **Radiopharm Theranostics** has entered into a research and option agreement with **Starpharma** to develop a novel radiotherapy asset.  **[1949257_0001213900-25-093349_ea025941901ex99-1_radio.htm:0]** 
- This collaboration aims to combine Radiopharm's radiopharmaceutical molecule with Starpharma's proprietary **DEP® platform technology** to create a new drug conjugate.  **[1949257_0001213900-25-093349_ea025941901ex99-1_radio.htm:0]** 
- Should Radiopharm exercise its exclusive option to license the developed asset, it would involve an **AUD $0.5 million option fee**, an **AUD $2 million upfront payment**, and potential **milestone payments of up to AUD $89 million**, in addition to royalties on net sales, payable to Starpharma.  **[1949257_0001213900-25-093349_ea025941901ex99-1_radio.htm:0]**

Radiopharm Theranostics Partners with Starpharma for Radiotherapy Development

- Radiopharm Theranostics Limited reported a **20.2% decrease** in loss from ordinary activities after tax, totaling **($36,703,089)** for the year ended **June 30, 2025**.  **[1949257_0001213900-25-082105_ea025521801ex99-1_radio.htm:0]** 
- Revenue from contracts with customers significantly increased by **1114.3%** to **$3,633,422** for the year ended **June 30, 2025**.  **[1949257_0001213900-25-082105_ea025521801ex99-1_radio.htm:0]** 
- Net assets grew to **$42,871,904** and cash reserves to **$29,116,835** as of **June 30, 2025**, primarily due to capital raises.  **[1949257_0001213900-25-082105_ea025521801ex99-1_radio.htm:0]** **[1949257_0001213900-25-082105_ea025521801ex99-1_radio.htm:3]** 
- The company increased its ownership in Radiopharm Ventures from 51% to **75%** on **August 26, 2024**.  **[1949257_0001213900-25-082105_ea025521801ex99-1_radio.htm:0]** 
- The financial statements for the year ended **June 30, 2025**, are currently undergoing audit, with the final audited report anticipated by mid-September 2025.  **[1949257_0001213900-25-082105_ea025521801ex99-1_radio.htm:0]**

Radiopharm Theranostics (RADX)